Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells

doi:10.1093/carcin/bgm263

淡江大學機構典藏 > 理學院 > 化學學系暨研究所 > 期刊論文 > Item 987654321/61568

請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/61568

題名:	Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells
作者:	Ou, Chien-Chih;Hsu, Shih-Chung;Hsieh, Yin-Hui;Tsou, Wan-Ling;Chuang, Tzu-Chao;Liu, Jah-Yao;Kao, Ming-Ching
貢獻者:	淡江大學化學學系
日期:	2008-02
上傳時間:	2013-05-31 11:35:31 (UTC+8)
出版者:	Oxford: Oxford University Press
摘要:	Interferon-γ (IFN-γ) is known to downregulate HER2 oncoprotein (p185HER2 or briefly p185) in prostate cancer cells. We demonstrate that the IFN-γ-induced retinoid-inducible gene 1 (RIG1) acts as a transrepressor of p185. Furthermore, we exhibit that RIG1 downregulates the activated (phosphorylated) form of p185 and phosphoinositide-3 kinase (PI3K)/serine/threonine-specific protein kinase (Akt) and the mammalian target of rapamycin (mTOR), downstream substrates of HER2. We also elucidate that heregulin (HRG) specifically restores the activation of p185 and Akt after their activities are reduced by RIG1. Additionally, expression of vascular endothelial growth factor (VEGF) increases through the HER2- and Akt/mTOR-signaling pathways, indicating that VEGF is downregulated by RIG1 within the cell. These findings suggest that RIG1 plays a role in IFN-γ-mediated therapy by downregulating p185 and its downstream PI3K/Akt/mTOR/VEGF-signaling pathway. These results may provide a new therapeutic mechanism for the clinical use of IFN-γ and RIG1.
關聯:	Carcinogenesis 29(2), pp.299-306
DOI:	10.1093/carcin/bgm263
顯示於類別:	[化學學系暨研究所] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
Downregulation of HER2 by RIG1 involves the PI3K Akt pathway in ovarian cancer cells.pdf		969Kb	Adobe PDF	1	檢視/開啟
index.html		0Kb	HTML	47	檢視/開啟

在機構典藏中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....